secwatch.observer — SEC 8-K summary
======================================

Issuer:     AXIM BIOTECHNOLOGIES, INC. (AXIM)
CIK:        0001514946
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001096906-23-001228
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AXIM Biotechnologies enters $20M equity purchase agreement with Cross & Company
-------------------------------------------------------------------------------

- Equity Purchase Agreement for up to $20M of common stock with an institutional investor (Cross & Company).
- Company may require investor to buy shares in puts of $10k-$250k, subject to volume limits.
- Purchase price set at 87.5% of lowest traded price during a 10-day valuation period after clearing.
- Agreement term up to 3 years; registration statement on Form S-1 required for resale of put shares.
- Issuance capped at 4.99% beneficial ownership; dilution potential from discounted share sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/0001096906-23-001228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514946/000109690623001228/axim-20230601.htm
  HTML page:      https://secwatch.observer/filing/0001096906-23-001228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer